Grafa News and Videos — Page 810

SLB (NYSE:SLB) announced that its OneSubsea joint venture was awarded a major engineering, procurement and construction contract by Eni for Phase 3 of the deepwater Baleine project offshore Côte d’Ivoire, covering subsea production systems for 13 wells.

Third Coast Bancshares (NYSE:TCBX) completed the sale of substantially all assets of its subsidiary Third Coast Commercial Capital to Gulf Coast Bank & Trust for approximately $27.5 million, generating a $3.5 million gain.

Aethlon Medical (NASDAQ:AEMD) reported that patients in the second cohort of its oncology feasibility study exhibited biological changes.

Diana Shipping (NYSE:DSX) extended its tender offer to acquire all outstanding shares of Genco Shipping & Trading (NYSE:GNK) it does not already own through July 24, 2026, after shareholders tendered 11.08 million shares.

Greenfire Resources (NYSE:GFR) agreed to acquire private thermal oil sands producer Connacher Oil and Gas for an estimated C$1.277 billion in cash, net of expected closing adjustments, expanding its production base and reserves position.

The Metals Royalty Company (NASDAQ:TMC) reported that its Mesabi Metallics iron ore royalty project in Nashwauk, Minnesota completed its first production blast on July 10, 2026, marking a step toward planned pellet production.

The Ethereum Foundation's Protocol Security team identified and patched a significant security vulnerability in the network's core software after deploying coordinated artificial intelligence agents to analyse the codebase.

Ocugen (NASDAQ:OCGN) signed a binding term sheet with Roots Pharmaceutical and strategic partner Al-Dhow International Holding to negotiate an exclusive license for OCU400, its investigational modifier gene therapy for retinitis pigmentosa, across the Middle East and North Africa region.

Alkermes (NASDAQ:ALKS) reported interim results from its ongoing long-term extension study of alixorexton in adults with narcolepsy type 1 and narcolepsy type 2, showing sustained improvements in wakefulness, sleepiness and patient-reported outcomes after 24 weeks.

Ionis Pharmaceuticals (NASDAQ:IONS) announced that the first participant has been dosed in the Phase 1-2 ASCEND study evaluating ION337, an investigational RNA-targeted medicine for children with Dravet syndrome, a rare neurological disorder.